Literature DB >> 10490438

Randomised trial of LHRH analogue treatment on final height in girls with onset of puberty aged 7.5-8.5 years.

A Cassio1, E Cacciari, A Balsamo, M Bal, D Tassinari.   

Abstract

OBJECTIVE: To study the effectiveness of luteinising hormone releasing hormone (LHRH) analogues in improving final height in girls affected by early puberty. PATIENTS: Forty six consecutive girls with onset of puberty aged 7.5-8.5 years randomly divided into two groups: one treated with 3.75 mg triptorelin intramuscularly every four weeks (group 1); and the other with no treatment (group 2).
RESULTS: Mean (SD) chronological age at onset of menarche was significantly higher in group 1 than in group 2 (11.9 (1.0) v 10.8 (0.7) years). However, mean (SD) height at menarche (152.7 (7.2) v 152.5 (5.7) cm) and mean (SD) growth after menarche (4.9 (3.0) v 5.4 (2.2) cm) were similar in both groups. The mean (SD) final height was similar in the two groups (group 1, 158.1 (6.2) cm; group 2, 158. 6 (6.0) cm) and not significantly different from target height. Fourteen of 20 patients in group 1 and 12 of 18 patients in group 2 showed final height equal to or higher than target height. Final heights of girls with poor initial height prognosis were significantly lower than those of girls with good prognosis, but in patients with the same initial height prognosis, both groups showed final heights similar and not significantly different from their target heights.
CONCLUSIONS: LHRH analogue has no apparent effect on final height in subjects with onset of puberty between 7.5 and 8.5 years.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10490438      PMCID: PMC1718086          DOI: 10.1136/adc.81.4.329

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  26 in total

1.  Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards.

Authors:  N BAYLEY; S R PINNEAU
Journal:  J Pediatr       Date:  1952-04       Impact factor: 4.406

2.  Final height of girls with central precocious puberty, untreated versus treated with cyproterone acetate or GnRH analogue. A comparative study with re-evaluation of predictions by the Bayley-Pinneau method.

Authors:  R Kauli; A Galatzer; L Kornreich; L Lazar; A Pertzelan; Z Laron
Journal:  Horm Res       Date:  1997

3.  Standards for children's height at ages 2-9 years allowing for heights of parents.

Authors:  J M Tanner; H Goldstein; R H Whitehouse
Journal:  Arch Dis Child       Date:  1970-12       Impact factor: 3.791

4.  Gonadotrophin-releasing hormone agonist treatment of central precocious puberty: an analysis of growth data in a developmental context.

Authors:  P A Boepple; M J Mansfield; J D Crawford; J F Crigler; R M Blizzard; W F Crowley
Journal:  Acta Paediatr Scand Suppl       Date:  1990

5.  Final height in central precocious puberty after long term treatment with a slow release GnRH agonist.

Authors:  W Oostdijk; B Rikken; S Schreuder; B Otten; R Odink; C Rouwé; M Jansen; W J Gerver; J Waelkens; S Drop
Journal:  Arch Dis Child       Date:  1996-10       Impact factor: 3.791

6.  Growth analysis up to final height and psychosocial adjustment of treated and untreated patients with precocious puberty.

Authors:  C E Schoevaart; S L Drop; B J Otten; F M Slijper; H J Degenhart
Journal:  Horm Res       Date:  1990

7.  Adult height in girls with idiopathic true precocious puberty.

Authors:  R Brauner; L Adan; F Malandry; D Zantleifer
Journal:  J Clin Endocrinol Metab       Date:  1994-08       Impact factor: 5.958

8.  Growth, bone maturation and height prediction after three years of therapy with the slow release GnRH-agonist Decapeptyl-Depot in children with central precocious puberty.

Authors:  R Hümmelink; W Oostdijk; C J Partsch; R J Odink; S L Drop; W G Sippell
Journal:  Horm Metab Res       Date:  1992-03       Impact factor: 2.936

9.  Long-term follow-up and final height in girls with central precocious puberty treated with luteinizing hormone-releasing hormone analogue nasal spray.

Authors:  E Cacciari; A Cassio; A Balsamo; C Colli; A Cicognani; P Pirazzoli; G Tani; L Brondelli; M Mandini; L Bovicelli
Journal:  Arch Pediatr Adolesc Med       Date:  1994-11

10.  Therapeutic use of pituitary desensitization with a long-acting lhrh agonist: a potential new treatment for idiopathic precocious puberty.

Authors:  W F Crowley; F Comite; W Vale; J Rivier; D L Loriaux; G B Cutler
Journal:  J Clin Endocrinol Metab       Date:  1981-02       Impact factor: 5.958

View more
  23 in total

1.  Quantitative calcaneal ultrasound parameters and bone mineral density at final height in girls treated with depot gonadotrophin-releasing hormone agonist for central precocious puberty or idiopathic short stature.

Authors:  Simone Kapteijns-van Kordelaar; Kees Noordam; Barto Otten; Joop van den Bergh
Journal:  Eur J Pediatr       Date:  2003-09-17       Impact factor: 3.183

2.  Final height in a patient with Laron syndrome after long-term therapy with rhlGF-I and short-term therapy with LHRH-analogue and oxandrolone during puberty.

Authors:  S Zucchini; E Scarano; L Baldazzi; L Mazzanti; P Pirazzoli; E Cacciari
Journal:  J Endocrinol Invest       Date:  2005-03       Impact factor: 4.256

3.  Adult height after spontaneous pubertal growth or GnRH analog treatment in girls with early puberty: a meta-analysis.

Authors:  Silvano Bertelloni; Francesco Massart; Mario Miccoli; Giampiero I Baroncelli
Journal:  Eur J Pediatr       Date:  2017-04-01       Impact factor: 3.183

4.  Growth in precocious puberty.

Authors:  Justin J Brown; Garry L Warne
Journal:  Indian J Pediatr       Date:  2006-01       Impact factor: 1.967

Review 5.  Central precocious puberty: current treatment options.

Authors:  Franco Antoniazzi; Giorgio Zamboni
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

Review 6.  Precocious puberty and normal variant puberty: definition, etiology, diagnosis and current management.

Authors:  Merih Berberoğlu
Journal:  J Clin Res Pediatr Endocrinol       Date:  2009-05-02

7.  Relationship between serum insulin-like growth factor-1, IGF binding protein-3 levels and body height before and after gonadotropin-releasing hormone agonist therapy.

Authors:  Han Sol Song; Won Bok Choi; Joon Sup Song; Il Tae Hwang; Seung Yang
Journal:  Ann Pediatr Endocrinol Metab       Date:  2014-12-31

8.  Models for predicting the adult height and age at first menstruation of girls with idiopathic central precocious puberty.

Authors:  Eloïse Giabicani; Pierre Lemaire; Raja Brauner
Journal:  PLoS One       Date:  2015-04-02       Impact factor: 3.240

Review 9.  Pros and cons of GnRHa treatment for early puberty in girls.

Authors:  Ruben H Willemsen; Daniela Elleri; Rachel M Williams; Ken K Ong; David B Dunger
Journal:  Nat Rev Endocrinol       Date:  2014-04-08       Impact factor: 43.330

10.  A mathematical model for predicting the adult height of girls with advanced puberty after spontaneous growth.

Authors:  Pierre Lemaire; Delphine Pierre; Jean-Baptiste Bertrand; Raja Brauner
Journal:  BMC Pediatr       Date:  2014-07-03       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.